Table of Content

1 Study Coverage
1.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Introduction
1.2 Market by Type
1.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 TJM-F92 Strain
1.2.3 GDr180 Strain
1.2.4 JXA1-R Strain
1.2.5 Other
1.3 Market by Application
1.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Farms
1.3.3 Individual
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Estimates and Forecasts 2018-2029
2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region
2.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2018-2024)
2.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2024-2029)
2.2.4 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2018-2029)
2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Estimates and Forecasts 2018-2029
2.4 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region
2.4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024)
2.4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029)
2.4.4 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Manufacturers
3.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Manufacturers (2018-2024)
3.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live in 2022
3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Manufacturers
3.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Manufacturers (2018-2024)
3.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue in 2022
3.3 Global Key Players of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Product Offered and Application
3.8 Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type
4.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historical Sales by Type (2018-2024)
4.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Sales by Type (2024-2029)
4.1.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2018-2029)
4.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type
4.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historical Revenue by Type (2018-2024)
4.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Revenue by Type (2024-2029)
4.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2018-2029)
4.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Type
4.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Type (2018-2024)
4.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application
5.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historical Sales by Application (2018-2024)
5.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Sales by Application (2024-2029)
5.1.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2018-2029)
5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application
5.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Historical Revenue by Application (2018-2024)
5.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecasted Revenue by Application (2024-2029)
5.2.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2018-2029)
5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Application
5.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Application (2018-2024)
5.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Type
6.1.1 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2029)
6.1.2 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2029)
6.2 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Application
6.2.1 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2029)
6.2.2 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2029)
6.3 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country
6.3.1 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2029)
6.3.3 US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Type
7.1.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2029)
7.1.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2029)
7.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Application
7.2.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2029)
7.2.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2029)
7.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country
7.3.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2029)
7.3.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size
8.1.1 China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (2018-2029)
8.1.2 China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2029)
8.2 China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Application
8.2.1 China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2029)
8.2.2 China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Type
9.1.1 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2029)
9.1.2 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2029)
9.2 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Application
9.2.1 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2029)
9.2.2 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2029)
9.3 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region
9.3.1 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2018-2029)
9.3.3 Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Type
10.1.1 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Application
10.2.1 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country
10.3.1 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Yongshun Creatures
11.1.1 Yongshun Creatures Company Information
11.1.2 Yongshun Creatures Overview
11.1.3 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Yongshun Creatures Recent Developments
11.2 Keqian Biology
11.2.1 Keqian Biology Company Information
11.2.2 Keqian Biology Overview
11.2.3 Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Keqian Biology Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Information
11.3.2 Boehringer Ingelheim Overview
11.3.3 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Boehringer Ingelheim Recent Developments
11.4 Sinovet
11.4.1 Sinovet Company Information
11.4.2 Sinovet Overview
11.4.3 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sinovet Recent Developments
11.5 Elanco
11.5.1 Elanco Company Information
11.5.2 Elanco Overview
11.5.3 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Elanco Recent Developments
11.6 MSD
11.6.1 MSD Company Information
11.6.2 MSD Overview
11.6.3 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 MSD Recent Developments
11.7 Cahic
11.7.1 Cahic Company Information
11.7.2 Cahic Overview
11.7.3 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Cahic Recent Developments
11.8 Ringpu
11.8.1 Ringpu Company Information
11.8.2 Ringpu Overview
11.8.3 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Ringpu Recent Developments
11.9 Baoling
11.9.1 Baoling Company Information
11.9.2 Baoling Overview
11.9.3 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Baoling Recent Developments
11.10 Jizhong
11.10.1 Jizhong Company Information
11.10.2 Jizhong Overview
11.10.3 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Jizhong Recent Developments
11.11 Dahuanong
11.11.1 Dahuanong Company Information
11.11.2 Dahuanong Overview
11.11.3 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Dahuanong Recent Developments
11.12 Hayao
11.12.1 Hayao Company Information
11.12.2 Hayao Overview
11.12.3 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Hayao Recent Developments
11.13 Pulike Biology
11.13.1 Pulike Biology Company Information
11.13.2 Pulike Biology Overview
11.13.3 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Pulike Biology Recent Developments
11.14 Tecon
11.14.1 Tecon Company Information
11.14.2 Tecon Overview
11.14.3 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Tecon Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Chain Analysis
12.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Production Mode & Process
12.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales and Marketing
12.4.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Channels
12.4.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors
12.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customers
13 Market Dynamics
13.1 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Trends
13.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
13.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
13.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
14 Key Findings in The Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of TJM-F92 Strain
Table 3. Major Manufacturers of GDr180 Strain
Table 4. Major Manufacturers of JXA1-R Strain
Table 5. Major Manufacturers of Other
Table 6. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2018-2024)
Table 11. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2024-2029)
Table 12. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024) & (Box)
Table 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029) & (Box)
Table 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2018-2024)
Table 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2024-2029)
Table 17. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Manufacturers (2018-2024) & (Box)
Table 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Manufacturers (2018-2024)
Table 19. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Manufacturers 2018-2024 (US$/Box)
Table 23. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live as of 2022)
Table 25. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Product Offered and Application
Table 27. Global Key Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (Box)
Table 30. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029) & (Box)
Table 31. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Type (2018-2024)
Table 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Type (2024-2029)
Table 33. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Type (2018-2024)
Table 36. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Type (2024-2029)
Table 37. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Type (2018-2024) & (US$/Box)
Table 38. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price Forecast by Type (2024-2029) & (US$/Box)
Table 39. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (Box)
Table 40. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029) & (Box)
Table 41. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Application (2018-2024)
Table 42. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Application (2024-2029)
Table 43. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Application (2018-2024)
Table 46. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Application (2024-2029)
Table 47. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price by Application (2018-2024) & (US$/Box)
Table 48. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Price Forecast by Application (2024-2029) & (US$/Box)
Table 49. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (Box)
Table 50. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029) & (Box)
Table 51. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (Box)
Table 54. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029) & (Box)
Table 55. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 61. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 62. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (Box)
Table 63. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029) & (Box)
Table 64. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (Box)
Table 67. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029) & (Box)
Table 68. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 74. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 75. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (Box)
Table 76. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029) & (Box)
Table 77. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (Box)
Table 80. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029) & (Box)
Table 81. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (Box)
Table 84. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029) & (Box)
Table 85. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (Box)
Table 88. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029) & (Box)
Table 89. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2018-2024) & (Box)
Table 95. Asia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2024-2029) & (Box)
Table 96. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2018-2024) & (Box)
Table 97. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2024-2029) & (Box)
Table 98. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2018-2024) & (Box)
Table 101. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2024-2029) & (Box)
Table 102. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2018-2024) & (Box)
Table 108. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2024-2029) & (Box)
Table 109. Yongshun Creatures Company Information
Table 110. Yongshun Creatures Description and Major Businesses
Table 111. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 112. Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Yongshun Creatures Recent Developments
Table 114. Keqian Biology Company Information
Table 115. Keqian Biology Description and Major Businesses
Table 116. Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 117. Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Keqian Biology Recent Developments
Table 119. Boehringer Ingelheim Company Information
Table 120. Boehringer Ingelheim Description and Major Businesses
Table 121. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 122. Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Boehringer Ingelheim Recent Developments
Table 124. Sinovet Company Information
Table 125. Sinovet Description and Major Businesses
Table 126. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 127. Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Sinovet Recent Developments
Table 129. Elanco Company Information
Table 130. Elanco Description and Major Businesses
Table 131. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 132. Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Elanco Recent Developments
Table 134. MSD Company Information
Table 135. MSD Description and Major Businesses
Table 136. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 137. MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. MSD Recent Developments
Table 139. Cahic Company Information
Table 140. Cahic Description and Major Businesses
Table 141. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 142. Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Cahic Recent Developments
Table 144. Ringpu Company Information
Table 145. Ringpu Description and Major Businesses
Table 146. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 147. Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Ringpu Recent Developments
Table 149. Baoling Company Information
Table 150. Baoling Description and Major Businesses
Table 151. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 152. Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Baoling Recent Developments
Table 154. Jizhong Company Information
Table 155. Jizhong Description and Major Businesses
Table 156. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 157. Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Jizhong Recent Developments
Table 159. Dahuanong Company Information
Table 160. Dahuanong Description and Major Businesses
Table 161. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 162. Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 163. Dahuanong Recent Developments
Table 164. Hayao Company Information
Table 165. Hayao Description and Major Businesses
Table 166. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 167. Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 168. Hayao Recent Developments
Table 169. Pulike Biology Company Information
Table 170. Pulike Biology Description and Major Businesses
Table 171. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 172. Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 173. Pulike Biology Recent Developments
Table 174. Tecon Company Information
Table 175. Tecon Description and Major Businesses
Table 176. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2018-2024)
Table 177. Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Model Numbers, Pictures, Descriptions and Specifications
Table 178. Tecon Recent Developments
Table 179. Key Raw Materials Lists
Table 180. Raw Materials Key Suppliers Lists
Table 181. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors List
Table 182. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customers List
Table 183. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Trends
Table 184. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Drivers
Table 185. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Challenges
Table 186. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Restraints
Table 187. Research Programs/Design for This Report
Table 188. Key Data Information from Secondary Sources
Table 189. Key Data Information from Primary Sources
List of Figures
Figure 1. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Picture
Figure 2. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Type in 2022 & 2029
Figure 4. TJM-F92 Strain Product Picture
Figure 5. GDr180 Strain Product Picture
Figure 6. JXA1-R Strain Product Picture
Figure 7. Other Product Picture
Figure 8. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Application in 2022 & 2029
Figure 10. Farms
Figure 11. Individual
Figure 12. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Report Years Considered
Figure 13. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue 2018-2029 (US$ Million)
Figure 15. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Region (2018-2029)
Figure 17. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales 2018-2029 ((Box)
Figure 18. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2018-2029) & (Box)
Figure 20. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2018-2029) & (Box)
Figure 22. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2018-2029) & (Box)
Figure 24. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2018-2029) & (Box)
Figure 26. Asia (excluding China) Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales YoY (2018-2029) & (Box)
Figure 28. Middle East, Africa and Latin America Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live in the World: Market Share by Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue in 2022
Figure 31. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2018-2029)
Figure 33. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2018-2029)
Figure 34. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2018-2029)
Figure 35. Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Country (2018-2029)
Figure 41. US & Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Country (2018-2029)
Figure 42. U.S. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2018-2029)
Figure 45. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type (2018-2029)
Figure 46. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Application (2018-2029)
Figure 47. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Application (2018-2029)
Figure 48. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Share by Country (2018-2029)
Figure 49. Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Share by Country (2018-2029)
Figure 50. Germany Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2029) & (US$ Million)
Figure 51. France Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue (2018-2029) & (US$ Million)
Figure 55. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2018-2029)
Figure 56. China Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Type